드러그인포 약품요약정보

허가정보

항목

내용

청구코드(KD코드)
비급여점검코드
상한금액

645904870[A01305351] [보험코드에 따른 약품기본정보 직접조회]
\0 원/1g(2002.01.01)(현재약가)
\134 원/1g(2001.04.01)(변경전약가)
[상병코드조회]
[질병코드조회]

빠른조회


요약정보	[효능] [용법] [금기] [신중투여] [이상반응]

상세정보	[효능] [용법] [경고] [금기] [신중투여] [이상반응] [일반주의] [상호작용] [임산부] [수유부] [소아] [고령자] [신장애환자] [간장애환자] [적용주의] [과량투여] [임상검사치] [보관] [기타]

제품성상

미백색의 크림 [제형정보 확인]

포장·유통단위

450g, 1's.

허가사항 원문조회

[허가사항 원문조회]

효능효과

[적응증 별 검색]

무좀, 완선, 소수포성 반상백선
[Drugbank 의 성분정보열람]
[Crotamiton][Lidocaine]

용법용량

* 절대 임의복용하지 마시고 반드시 의사 또는 약사와 상담하시기 바랍니다.

[처방약어]
[주성분코드:344000CCM 에 따른 심사지침열람]
1일 2-3회, 적량을 환부에 도포한다.
[제형별복약지도]

[BMI지수 계산] [Body Surface Area 계산] [Cockcroft-Gault GFR 계산] [MDRD GFR 계산]

[복용을 잊은 경우 대처법]

신중투여

약이나 화장품에 의한 알레르기 증상(발진, 발적, 가려움, 옻 등)을 일으킨 적이 있는 환자
1. 환부가 안면이거나 광범위한 환자
2. 습윤이나 진무름이 심한 환자
3. 영.유아
4. 의사의 치료를 받고 있는 환자
이 약은 프로필렌글리콜을 함유하고 있으므로, 이 성분에 과민하거나 알레르기 병력이 있는 환자에는 신중히 투여한다.

이상반응

발진, 발적, 가려움, 옻, 작열감

[주요 이상반응정보]

Related FDA Approved Drug

기준 성분:SALICYLIC ACID
NEOPASALATE (AMINOSALICYLATE SODIUM; AMINOSALICYLIC ACID)
PARASAL (AMINOSALICYLIC ACID)
PASER (AMINOSALICYLIC ACID)
REZIPAS (AMINOSALICYLIC ACID RESIN COMPLEX)
기준 성분:LIDOCAINE
AKTEN (LIDOCAINE HYDROCHLORIDE)
ALPHACAINE (LIDOCAINE)
ALPHACAINE HYDROCHLORIDE (LIDOCAINE HYDROCHLORIDE)
ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE (EPINEPHRINE; LIDOCAINE HYDROCHLORIDE)
ANESTACON (LIDOCAINE HYDROCHLORIDE)
DECADRON W/ XYLOCAINE (DEXAMETHASONE SODIUM PHOSPHATE; LIDOCAINE HYDROCHLORIDE)
DENTIPATCH (LIDOCAINE)
DUOCAINE (BUPIVACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDE)
EMBOLEX (DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE)
EMLA (LIDOCAINE; PRILOCAINE)
IONTOCAINE (EPINEPHRINE; LIDOCAINE HYDROCHLORIDE)
LANABIOTIC (BACITRACIN ZINC; LIDOCAINE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE)
LARYNG-O-JET KIT (LIDOCAINE HYDROCHLORIDE)
LARYNGOTRACHEAL ANESTHESIA KIT (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE (LIDOCAINE)
LIDOCAINE AND PRILOCAINE (LIDOCAINE; PRILOCAINE)
LIDOCAINE AND TETRACAINE (LIDOCAINE; TETRACAINE)
LIDOCAINE HYDROCHLORIDE (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE 0.1% AND DEXTROSE 5% IN PLASTIC CONTAINER (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5% (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE (EPINEPHRINE; LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE VISCOUS (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE (EPINEPHRINE; LIDOCAINE HYDROCHLORIDE)
LIDOCAINE VISCOUS (LIDOCAINE HYDROCHLORIDE)
LIDOCATON (EPINEPHRINE; LIDOCAINE HYDROCHLORIDE)
LIDODERM (LIDOCAINE)
LIDOPEN (LIDOCAINE HYDROCHLORIDE)
LIDOSITE TOPICAL SYSTEM KIT (EPINEPHRINE; LIDOCAINE HYDROCHLORIDE)
LIGNOSPAN FORTE (EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE)
LIGNOSPAN STANDARD (EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE)
LTA II KIT (LIDOCAINE HYDROCHLORIDE)
OCTOCAINE (EPINEPHRINE; LIDOCAINE HYDROCHLORIDE)
ORAQIX (LIDOCAINE; PRILOCAINE)
PEDIATRIC LTA KIT (LIDOCAINE HYDROCHLORIDE)
ROCEPHIN KIT (CEFTRIAXONE SODIUM; LIDOCAINE)
SYNERA (LIDOCAINE; TETRACAINE)
TERRAMYCIN (LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINE)
XYLOCAINE (LIDOCAINE)
XYLOCAINE 1.5% W/ DEXTROSE 7.5% (LIDOCAINE HYDROCHLORIDE)
XYLOCAINE 4% PRESERVATIVE FREE (LIDOCAINE HYDROCHLORIDE)
XYLOCAINE 5% W/ GLUCOSE 7.5% (LIDOCAINE HYDROCHLORIDE)
XYLOCAINE DENTAL (LIDOCAINE HYDROCHLORIDE)
XYLOCAINE DENTAL WITH EPINEPHRINE (EPINEPHRINE; LIDOCAINE HYDROCHLORIDE)
XYLOCAINE PRESERVATIVE FREE (LIDOCAINE HYDROCHLORIDE)
XYLOCAINE VISCOUS (LIDOCAINE HYDROCHLORIDE)
XYLOCAINE W/ EPINEPHRINE (EPINEPHRINE; LIDOCAINE HYDROCHLORIDE)
ZINGO (LIDOCAINE HYDROCHLORIDE)
기준 성분:GLYCYLIC ACID
기준 성분:CROTAMITON
CROTAN (CROTAMITON)
EURAX (CROTAMITON)

정보요약

드럭인포 의약품 요약/상세정보

코드 및 분류정보

항목	내용
대표코드	8806459048707
BIT 약효분류	외용 항진균제 (Antifungals : Skin & Mucous Membrane)
ATC 코드	Other antifungals for topical use / D01AE [코드분류상세설명] [ATC코드예측]
복지부분류코드	265 (기생성 피부질환용제 )
주성분코드 분석 및 중복처방 검토	[주성분코드 분석 및 중복처방 검토]
Drugs By Indication	[전체보기]
Drugs By Classification	[전체보기]

제품정보

항목	내용
청구코드(KD코드) 비급여점검코드 상한금액	645904870[A01305351] [보험코드에 따른 약품기본정보 직접조회] \0 원/1g(2002.01.01)(최신약가) \134 원/1g(2001.04.01)(변경전약가) [상병코드조회] [질병코드집 다운로드]
제품성상	미백색의 크림 [제형정보 확인]
포장·유통단위	450g, 1's.
동일주성분코드 검색순위	유료정보입니다.

복약정보

항목

내용

LACTmed 바로가기

[바로가기]

약리작용

유료정보입니다.

복약지도

유료정보입니다.

임부에대한투여

*	전체임신 기간별로 여러등급이 존재할 수 있으며 가장 위험도가 높은 정보만 보여집니다. 단, 복합제의 경우 모든 복합제성분에 대한 임부투여등급이 표시된것은 절대 아니며 표시된것중에 가장 위험도가 높은 정보만 나타납니다.

FDA : C등급

*	상기 임부투여에 대한 정보는 전산처리 되면서 입력 오류 가능성이 존재합니다. 오류 가능성을 최소화하기 위하여 많은 노력을 기울이고 있으나, 그 정확성에 대하여 확신을 드릴 수 없습니다. 이에 대해 회사는 책임을 지지 않습니다.
*	반드시 공신력 있는 문헌을 다시 한번 참고 하시기 바라며 의사 또는 약사의 판단에 따라 투여여부가 결정되어야 합니다.

신장애, 간장애시
용량조절

유료정보입니다.

Pharmacokinetics

유료정보입니다.

병용금기 및 연령대금기 근거조회

[병용금기 및 연령대금기 근거조회]

제형별 복약지도

[크림]

보관상 주의

조제시 주의

심사정보

항목	내용
DUR 관련 고시	[병용연령금기 의약품 / 임부금기 의약품 / 비용효과적 함량 의약품 / 안전성 관련 급여중지 의약품]

학술정보

항목	내용
DUR (의약품사용평가)	병용금기 : 고시된 병용금기 내용은 없습니다. [상호작용/병용금기검색] 연령대금기 : 고시된 연령금기 내용은 없습니다. [연령대금기상세검색]
독성정보	Lidocaine에 대한 독성정보 : 정보보기 Salicylic acid에 대한 독성정보 : 정보보기 출처: 국립독성과학원 독성물질정보DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do
Mechanism of Action	Crotamiton에 대한 Mechanism_Of_Action 정보 Crotamiton relieves itching by producing what is called a counter-irritation. As crotamiton evaporates from the skin, it produces a cooling effect. This cooling effect helps to divert your body's attention away from the itching. Lidocaine에 대한 Mechanism_Of_Action 정보 Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action. Tolnaftate에 대한 Mechanism_Of_Action 정보 Topical - Fungicidal; exact mechanism unknown; however, it has been reported to distort the hyphae and to stunt mycelial growth in susceptible organisms.
Pharmacology	Crotamiton에 대한 Pharmacology 정보 Crotamiton is usually used to treat pruritis (itching of the skin) caused by scabies or sunburn. Crotamiton relieves itching by producing what is called a counter-irritation. As crotamiton evaporates from the skin, it produces a cooling effect. This cooling effect helps to divert your body's attention away from the itching. Due to this cooling effect it is also effective for the relief of sunburn. The drug is also believed to kill scabies through an unknown mechanism. Lidocaine에 대한 Pharmacology 정보 Lidocaine is an anesthetic agent indicated for production of local or regional anesthesia and in the treatment of ventricular tachycardia occurring during cardiac manipulation, such as surgery or catheterization, or which may occur during acute myocardial infarction, digitalis toxicity, or other cardiac diseases. The mode of action of the antiarrhythmic effect of Lidocaine appears to be similar to that of procaine, procainamide and quinidine. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole. The sinoatrial node is, however, unaffected. In contrast to the latter 3 drugs, Lidocaine in therapeutic doses does not produce a significant decrease in arterial pressure or in cardiac contractile force. In larger doses, lidocaine may produce circulatory depression, but the magnitude of the change is less than that found with comparable doses of procainamide. Tolnaftate에 대한 Pharmacology 정보 Tolnaftate is a synthetic over-the-counter anti-fungal agent.
Metabolism	Crotamiton에 대한 Metabolism 정보 # Phase_1_Metabolizing_Enzyme:Not Available Lidocaine에 대한 Metabolism 정보 # Phase_1_Metabolizing_Enzyme:Cytochrome P450 1A2 (CYP1A2)Cytochrome P450 2D6 (CYP2D6)
Protein Binding	Crotamiton에 대한 단백결합 정보 Not Available Lidocaine에 대한 단백결합 정보 60-80% Tolnaftate에 대한 단백결합 정보 Not Available
Half-life	Crotamiton에 대한 반감기 정보 Not Available Lidocaine에 대한 반감기 정보 109 minutes Tolnaftate에 대한 반감기 정보 Not Available
Absorption	Crotamiton에 대한 Absorption 정보 10 % absorbed when applied locally. Lidocaine에 대한 Absorption 정보 Information derived from diverse formulations, concentrations and usages reveals that lidocaine is completely absorbed following parenteral administration, its rate of absorption depending, for example, upon various factors such as the site of administration and the presence or absence of a vasoconstrictor agent. Tolnaftate에 대한 Absorption 정보 Not Available
Pharmacokinetics	Tolnaftate의 약물동력학자료 작용발현시간 : 치료를 시작한 지 24-72 시간 이내에 반응이 나타난다. Lidocaine의 약물동력학자료 효과발현시간 (1회 bolus 용량으로서) : 45-90초 작용지속시간 : 10-25분 분포 (Vd) : 많은 요인에 따라 변화되며, 울혈성 심부전과 간질환에서는 분포용적이 감소됨 단백결합 : 60-80%, α₁-acid glycoprotein과 결합 대사 : 간에서 90% 대사 활성형 대사체인 monoethylglycinexylidide(MEGX)와 glycinexylidide(GX)가 축적되어 중추신경계 독성을 유발할 수 있다. 반감기 (biphasic) : 울혈성 심부전, 간질환, 쇼크, 중증의 신질환에서 증가 초기 : 7-30분 말기 : 영아, 미숙아 : 3.2시간, 성인 : 1.5-2시간 Salicylic Acid의 약물동력학자료 생체내이용률 : methyl salicylate 연고제 : 15-22% 분포 : 분포용적 : 0.17 L/kg 단백결합 : 50-80% 혈중최고농도 도달시간 : 외용 : 밀봉포대법 적용시 5시간 이내 소실 : 뇨중 배설형태는 경구와는 약간 달라서, 외용시 glucuronide 포합체 (42%)가 상대적으로 많으며, salicyluric acid (52%)와 미변화체 (6%)는 상대적으로 적다.
Biotransformation	Crotamiton에 대한 Biotransformation 정보 Not Available Lidocaine에 대한 Biotransformation 정보 Primarily hepatic.
Toxicity	Crotamiton에 대한 Toxicity 정보 Not Available Lidocaine에 대한 Toxicity 정보 The oral LD 50 of lidocaine HCl in non-fasted female rats is 459 (346-773) mg/kg (as the salt) and 214 (159-324) mg/kg (as the salt) in fasted female rats. Symptoms of overdose include convulsions, hypoxia, acidosis, bradycardia, arrhythmias and cardiac arrest. Tolnaftate에 대한 Toxicity 정보 Oral rat LD50: 891 mg/kg. Inhalation rat LC50: > 900 mg/m3/1hr. Irritation: skin rabbit: 500 mg/24H mild. Eye rabbit: 100 mg severe. Investigated a mutagen and reproductive effector.
Drug Interactions	Crotamiton에 대한 Drug_Interactions 정보 Acetohexamide The beta-blocker decreases the symptoms of hypoglycemiaChlorpropamide The beta-blocker decreases the symptoms of hypoglycemiaCimetidine Cimetidine increases the effect of the beta-blockerClonidine Increased hypertension when clonidine stoppedDisopyramide The beta-blocker increases toxicity of disopyramideGliclazide The beta-blocker decreases the symptoms of hypoglycemiaGlipizide The beta-blocker decreases the symptoms of hypoglycemiaGlisoxepide The beta-blocker decreases the symptoms of hypoglycemiaGlibenclamide The beta-blocker decreases the symptoms of hypoglycemiaGlycodiazine The beta-blocker decreases the symptoms of hypoglycemiaInsulin The beta-blocker decreases the symptoms of hypoglycemiaLidocaine The beta-blocker increases the effect and toxicity of lidocainePropafenone Propafenone increases the effect of beta-blockerRepaglinide The beta-blocker decreases the symptoms of hypoglycemiaRifampin Rifampin decreases the effect of the metabolized beta-blockerTelithromycin Telithromycin may possibly increase metoprolol effectTolazamide The beta-blocker decreases the symptoms of hypoglycemiaTolbutamide The beta-blocker decreases the symptoms of hypoglycemiaAmobarbital The barbiturate decreases the effect of metabolized beta-blockerAprobarbital The barbiturate decreases the effect of metabolized beta-blockerButalbital The barbiturate decreases the effect of metabolized beta-blockerButabarbital The barbiturate decreases the effect of metabolized beta-blockerButethal The barbiturate decreases the effect of metabolized beta-blockerDihydroquinidine barbiturate The barbiturate decreases the effect of metabolized beta-blockerHeptabarbital The barbiturate decreases the effect of metabolized beta-blockerHexobarbital The barbiturate decreases the effect of metabolized beta-blockerMethohexital The barbiturate decreases the effect of metabolized beta-blockerMethylphenobarbital The barbiturate decreases the effect of metabolized beta-blockerPentobarbital The barbiturate decreases the effect of metabolized beta-blockerPhenobarbital The barbiturate decreases the effect of metabolized beta-blockerPrimidone The barbiturate decreases the effect of metabolized beta-blockerQuinidine barbiturate The barbiturate decreases the effect of metabolized beta-blockerSecobarbital The barbiturate decreases the effect of metabolized beta-blockerTalbutal The barbiturate decreases the effect of metabolized beta-blockerCitalopram The SSRI increases the effect of the beta-blockerEscitalopram The SSRI increases the effect of the beta-blockerFluoxetine The SSRI increases the effect of the beta-blockerSertraline The SSRI increases the effect of the beta-blockerParoxetine The SSRI increases the effect of the beta-blockerDihydroergotamine Ischemia with risk of gangreneDihydroergotoxine Ischemia with risk of gangreneErgonovine Ischemia with risk of gangreneErgotamine Ischemia with risk of gangreneMethysergide Ischemia with risk of gangreneVerapamil Increased effect of both drugsHydralazine Increased effect of both drugsDiltiazem Increased risk of bradycardiaEpinephrine Hypertension, then bradycardiaFenoterol AntagonismFormoterol AntagonismIsoproterenol AntagonismOrciprenaline AntagonismPirbuterol AntagonismPrazosin Risk of hypotension at the beginning of therapyProcaterol AntagonismSalbutamol AntagonismSalmeterol AntagonismTerbutaline AntagonismIbuprofen Risk of inhibition of renal prostaglandinsIndomethacin Risk of inhibition of renal prostaglandinsPiroxicam Risk of inhibition of renal prostaglandins Lidocaine에 대한 Drug_Interactions 정보 Not Available Tolnaftate에 대한 Drug_Interactions 정보 Not Available
CYP450 Drug Interaction	[CYP450 Table직접조회]
Food Interaction	Crotamiton에 대한 Food Interaction 정보 Not Available Lidocaine에 대한 Food Interaction 정보 Not Available Tolnaftate에 대한 Food Interaction 정보 Not Available
Drug Target	[Drug Target]
Description	Crotamiton에 대한 Description 정보 Crotamiton is a scabicidal and antipruritic agent available as a cream or lotion for topical use only. It is a colorless to slightly yellowish oil, having a faint amine-like odor. It is miscible with alcohol and with methanol. Lidocaine에 대한 Description 정보 A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of procaine but its duration of action is shorter than that of bupivacaine or prilocaine. [PubChem] Tolnaftate에 대한 Description 정보 Tolnaftate is a synthetic over-the-counter anti-fungal agent. It may come as a cream, powder, spray, or liquid aerosol, and is used to treat jock itch, athlete's foot and ringworm. It is sold under several brand names, most notably Tinactin (Schering-Plough Corporation) and Odor Eaters (Combe Incorporated). Other brands are Absorbine, Aftate, Desenex, Genaspor, NP 27, and Ting.
Dosage Form	Crotamiton에 대한 Dosage_Form 정보 Cream Topical Lidocaine에 대한 Dosage_Form 정보 Aerosol TopicalAerosol, metered TopicalCream TopicalGel TopicalJelly TopicalJelly UrethralLiquid BuccalLiquid DentalLiquid InfiltrationLiquid IntravenousLiquid OralLiquid TopicalLotion TopicalOintment TopicalSolution InfiltrationSolution IntramuscularSolution IntravenousSolution OralSolution TopicalSpray TopicalSwab Topical Tolnaftate에 대한 Dosage_Form 정보 Aerosol TopicalCream TopicalGel TopicalLiquid TopicalPowder TopicalSpray TopicalSwab Topical
Drug Category	Crotamiton에 대한 Drug_Category 정보 Antiparasitic AgentsAntipruriticsPesticidesScabicides Lidocaine에 대한 Drug_Category 정보 AnestheticsAnesthetics, LocalAnti-Arrhythmia AgentsAntiarrhythmic Agents Tolnaftate에 대한 Drug_Category 정보 Antifungal Agents
Smiles String Canonical	Crotamiton에 대한 Smiles_String_canonical 정보 CCN(C(=O)C=CC)C1=CC=CC=C1C Lidocaine에 대한 Smiles_String_canonical 정보 CCN(CC)CC(=O)NC1=C(C)C=CC=C1C Tolnaftate에 대한 Smiles_String_canonical 정보 CN(C(=S)OC1=CC2=CC=CC=C2C=C1)C1=CC=CC(C)=C1
Smiles String Isomeric	Crotamiton에 대한 Smiles_String_isomeric 정보 CCN(C(=O)\C=C\C)C1=CC=CC=C1C Lidocaine에 대한 Smiles_String_isomeric 정보 CCN(CC)CC(=O)NC1=C(C)C=CC=C1C Tolnaftate에 대한 Smiles_String_isomeric 정보 CN(C(=S)OC1=CC2=CC=CC=C2C=C1)C1=CC=CC(C)=C1
InChI Identifier	Crotamiton에 대한 InChI_Identifier 정보 InChI=1/C13H17NO/c1-4-8-13(15)14(5-2)12-10-7-6-9-11(12)3/h4,6-10H,5H2,1-3H3 Lidocaine에 대한 InChI_Identifier 정보 InChI=1/C14H22N2O/c1-5-16(6-2)10-13(17)15-14-11(3)8-7-9-12(14)4/h7-9H,5-6,10H2,1-4H3,(H,15,17)/f/h15H Tolnaftate에 대한 InChI_Identifier 정보 InChI=1/C19H17NOS/c1-14-6-5-9-17(12-14)20(2)19(22)21-18-11-10-15-7-3-4-8-16(15)13-18/h3-13H,1-2H3
Chemical IUPAC Name	Crotamiton에 대한 Chemical_IUPAC_Name 정보 N-ethyl-N-(2-methylphenyl)but-2-enamide Lidocaine에 대한 Chemical_IUPAC_Name 정보 2-diethylamino-N-(2,6-dimethylphenyl)acetamide Tolnaftate에 대한 Chemical_IUPAC_Name 정보 O-naphthalen-2-yl [methyl-(3-methylphenyl)amino]methanethioate
Drug-Induced Toxicity Related Proteins	DOCA 의 Drug-Induced Toxicity Related Protein정보 Replated Protein:Aquaporin-2 Drug:DOCA Toxicity:hypertension. [바로가기] LIDOCAINE 의 Drug-Induced Toxicity Related Protein정보 Replated Protein:glucose-regulated protein Drug:lidocaine Toxicity:intestinal disorder. [바로가기] Replated Protein:Alkaline phosphatase Drug:lidocaine Toxicity:lidocaine induced hepatitis. [바로가기] Replated Protein:C-reactive protein Drug:lidocaine Toxicity:fever. [바로가기] Replated Protein:C-reactive protein Drug:lidocaine Toxicity:lidocaine induced hepatitis. [바로가기] Replated Protein:Alpha-1-acid glycoprotein Drug:lidocaine Toxicity:lidocaine tolerance. [바로가기] Replated Protein:Gamma-glutamyltranspeptidase Drug:lidocaine Toxicity:fever. [바로가기] Replated Protein:Alkaline phosphatase Drug:lidocaine Toxicity:fever. [바로가기] Replated Protein:Gamma-glutamyltranspeptidase Drug:lidocaine Toxicity:lidocaine induced hepatitis. [바로가기]

사용자컨텐츠

항목

내용

핵심 요약 정보